Novel approach for oligospermia (NAPO) - Protocol for a randomized controlled trial.

ABSTRACT:

Background

Infertility affects millions of couples globally, with up to 40-50 % of cases linked to impaired semen quality. Insemination or in vitro fertilization are used frequently, regardless of the cause of infertility due to the lack of specific medical interventions for male infertility. Denosumab, an antibody blocking RANKL signaling, may enhance semen quality in infertile men. This randomized controlled trial evaluates if denosumab improves spermatogenesis in men with severely impaired semen quality identified by serum AMH levels as a predictive marker.

Methods

NAPO is a single-center, sponsor-investigator-initiated, placebo-controlled, double-blinded randomized trial. Subjects will be randomized in a 2:1 fashion to receive either denosumab 60 mg subcutaneously or a p

SUBMITTER: Yahyavi SK 

PROVIDER: S-EPMC11395747 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature